Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perioperative Propranolol and Etodolac in Breast Cancer Surgery
NCT00502684Phase 2Unknown
- Sponsor
- Kaplan Medical Center
- Start
- Jun 2014
- Primary completion
- Jan 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of propranolol and etodolac in breast cancer (3 arms), sponsored by Kaplan Medical Center. Primary endpoints: Cytotoxic activity of NK cells against K562 target cells at Day 1, Serum levels of Th1, Th2 and inflammatory cytokines at Day 1 and 6 more. Status: unknown.
02
Drugs
propranololetodolac
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00502684.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00502684.